Protocol Ledger

NCT06760546 · Phase III · RECRUITING

A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)

Interventional Phase III clinical trial protocol NCT06760546 sponsored by Rhythm Pharmaceuticals in Endocrinology, Obesity, and Metabolic, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-09-23 Enrollment: 39 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06760546
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)39 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06760546
Protocol FieldVerified Registry Value
NCT IdentifierNCT06760546
Consolidated Lead SponsorRhythm Pharmaceuticals
Therapeutic Condition CohortEndocrinology, Obesity, and Metabolic
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment39 participants (ESTIMATED)
Registered Start Date2025-09-23
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Endocrinology, Obesity, and Metabolic Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI